Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter

Paul A. Volberding, Stephen W. Lagakos, Matthew A. Koch, Carla Pettinelli, Maureen W. Myers, David K. Booth, Henry H. Balfour, Richard C. Reichman, John A. Bartlett, Martin S. Hirsch, Robert L. Murphy, W. David Hardy, Ruy Soeiro, Margaret A Fischl, John G. Bartlett, Thomas C. Merigan, Newton E. Hyslop, Douglas D. Richman, Fred T. Valentine, Lawrence Corey

Research output: Contribution to journalArticle

1050 Citations (Scopus)

Abstract

Zidovudine (AZT) is a potent inhibitor of the replication of the human immunodeficiency virus (HIV), and it has been shown to improve survival in advanced HIV disease. We conducted a randomized, double-blind trial in adults with asymptomatic HIV infection who had CD4+ cell counts of fewer than 500 per cubic millimeter on entry into the study. The subjects (92 percent male) were randomly assigned to one of three treatment groups: placebo (428 subjects); zidovudine, 500 mg per day (453); or zidovudine, 1500 mg per day (457). After a mean follow-up of 55 weeks (range, 19 to 107), 33 of the subjects assigned to placebo had the acquired immunodeficiency syndrome (AIDS), as compared with 11 of those assigned to receive 500 mg of zidovudine (P = 0.002; relative risk, 2.8; 95 percent confidence interval, 1.4 to 5.6) and 14 of those assigned to receive 1500 mg of zidovudine (P = 0.05; relative risk, 1.9; 95 percent confidence interval, 1.0 to 3.5). In the three treatment groups, the rates of progression (per 100 person-years) to either AIDS or advanced AIDS-related complex were 7.6, 3.6, and 4.3, respectively. As compared with those assigned to placebo, the subjects in the zidovudine groups had significant increases in the number of CD4+ cells and significant declines in p24 antigen levels. In the 1500-mg zidovudine group, severe hematologic toxicity (anemia or neutropenia) was more frequent than in the other groups (P<0.0001). In the 500-mg zidovudine group, nausea was the only toxicity that was significantly more frequent (in 3.3 percent) than in the placebo group (P = 0.001). We conclude that zidovudine is safe and effective in persons with asymptomatic HIV infection and fewer than 500 CD4+ cells per cubic millimeter. Additional study will be required to determine whether such treatment will ultimately improve survival for persons infected with HIV.

Original languageEnglish
Pages (from-to)941-949
Number of pages9
JournalNew England Journal of Medicine
Volume322
Issue number14
StatePublished - Apr 5 1990

Fingerprint

Zidovudine
Virus Diseases
HIV
Placebos
Acquired Immunodeficiency Syndrome
Confidence Intervals
Survival
CD4 Lymphocyte Count
Neutropenia
Nausea
Anemia
Therapeutics
Cell Count
Antigens

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Volberding, P. A., Lagakos, S. W., Koch, M. A., Pettinelli, C., Myers, M. W., Booth, D. K., ... Corey, L. (1990). Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. New England Journal of Medicine, 322(14), 941-949.

Zidovudine in asymptomatic human immunodeficiency virus infection : A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. / Volberding, Paul A.; Lagakos, Stephen W.; Koch, Matthew A.; Pettinelli, Carla; Myers, Maureen W.; Booth, David K.; Balfour, Henry H.; Reichman, Richard C.; Bartlett, John A.; Hirsch, Martin S.; Murphy, Robert L.; Hardy, W. David; Soeiro, Ruy; Fischl, Margaret A; Bartlett, John G.; Merigan, Thomas C.; Hyslop, Newton E.; Richman, Douglas D.; Valentine, Fred T.; Corey, Lawrence.

In: New England Journal of Medicine, Vol. 322, No. 14, 05.04.1990, p. 941-949.

Research output: Contribution to journalArticle

Volberding, PA, Lagakos, SW, Koch, MA, Pettinelli, C, Myers, MW, Booth, DK, Balfour, HH, Reichman, RC, Bartlett, JA, Hirsch, MS, Murphy, RL, Hardy, WD, Soeiro, R, Fischl, MA, Bartlett, JG, Merigan, TC, Hyslop, NE, Richman, DD, Valentine, FT & Corey, L 1990, 'Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter', New England Journal of Medicine, vol. 322, no. 14, pp. 941-949.
Volberding, Paul A. ; Lagakos, Stephen W. ; Koch, Matthew A. ; Pettinelli, Carla ; Myers, Maureen W. ; Booth, David K. ; Balfour, Henry H. ; Reichman, Richard C. ; Bartlett, John A. ; Hirsch, Martin S. ; Murphy, Robert L. ; Hardy, W. David ; Soeiro, Ruy ; Fischl, Margaret A ; Bartlett, John G. ; Merigan, Thomas C. ; Hyslop, Newton E. ; Richman, Douglas D. ; Valentine, Fred T. ; Corey, Lawrence. / Zidovudine in asymptomatic human immunodeficiency virus infection : A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. In: New England Journal of Medicine. 1990 ; Vol. 322, No. 14. pp. 941-949.
@article{ef21f2aba6f148fdae70f9d4cb7342cb,
title = "Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter",
abstract = "Zidovudine (AZT) is a potent inhibitor of the replication of the human immunodeficiency virus (HIV), and it has been shown to improve survival in advanced HIV disease. We conducted a randomized, double-blind trial in adults with asymptomatic HIV infection who had CD4+ cell counts of fewer than 500 per cubic millimeter on entry into the study. The subjects (92 percent male) were randomly assigned to one of three treatment groups: placebo (428 subjects); zidovudine, 500 mg per day (453); or zidovudine, 1500 mg per day (457). After a mean follow-up of 55 weeks (range, 19 to 107), 33 of the subjects assigned to placebo had the acquired immunodeficiency syndrome (AIDS), as compared with 11 of those assigned to receive 500 mg of zidovudine (P = 0.002; relative risk, 2.8; 95 percent confidence interval, 1.4 to 5.6) and 14 of those assigned to receive 1500 mg of zidovudine (P = 0.05; relative risk, 1.9; 95 percent confidence interval, 1.0 to 3.5). In the three treatment groups, the rates of progression (per 100 person-years) to either AIDS or advanced AIDS-related complex were 7.6, 3.6, and 4.3, respectively. As compared with those assigned to placebo, the subjects in the zidovudine groups had significant increases in the number of CD4+ cells and significant declines in p24 antigen levels. In the 1500-mg zidovudine group, severe hematologic toxicity (anemia or neutropenia) was more frequent than in the other groups (P<0.0001). In the 500-mg zidovudine group, nausea was the only toxicity that was significantly more frequent (in 3.3 percent) than in the placebo group (P = 0.001). We conclude that zidovudine is safe and effective in persons with asymptomatic HIV infection and fewer than 500 CD4+ cells per cubic millimeter. Additional study will be required to determine whether such treatment will ultimately improve survival for persons infected with HIV.",
author = "Volberding, {Paul A.} and Lagakos, {Stephen W.} and Koch, {Matthew A.} and Carla Pettinelli and Myers, {Maureen W.} and Booth, {David K.} and Balfour, {Henry H.} and Reichman, {Richard C.} and Bartlett, {John A.} and Hirsch, {Martin S.} and Murphy, {Robert L.} and Hardy, {W. David} and Ruy Soeiro and Fischl, {Margaret A} and Bartlett, {John G.} and Merigan, {Thomas C.} and Hyslop, {Newton E.} and Richman, {Douglas D.} and Valentine, {Fred T.} and Lawrence Corey",
year = "1990",
month = "4",
day = "5",
language = "English",
volume = "322",
pages = "941--949",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "14",

}

TY - JOUR

T1 - Zidovudine in asymptomatic human immunodeficiency virus infection

T2 - A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter

AU - Volberding, Paul A.

AU - Lagakos, Stephen W.

AU - Koch, Matthew A.

AU - Pettinelli, Carla

AU - Myers, Maureen W.

AU - Booth, David K.

AU - Balfour, Henry H.

AU - Reichman, Richard C.

AU - Bartlett, John A.

AU - Hirsch, Martin S.

AU - Murphy, Robert L.

AU - Hardy, W. David

AU - Soeiro, Ruy

AU - Fischl, Margaret A

AU - Bartlett, John G.

AU - Merigan, Thomas C.

AU - Hyslop, Newton E.

AU - Richman, Douglas D.

AU - Valentine, Fred T.

AU - Corey, Lawrence

PY - 1990/4/5

Y1 - 1990/4/5

N2 - Zidovudine (AZT) is a potent inhibitor of the replication of the human immunodeficiency virus (HIV), and it has been shown to improve survival in advanced HIV disease. We conducted a randomized, double-blind trial in adults with asymptomatic HIV infection who had CD4+ cell counts of fewer than 500 per cubic millimeter on entry into the study. The subjects (92 percent male) were randomly assigned to one of three treatment groups: placebo (428 subjects); zidovudine, 500 mg per day (453); or zidovudine, 1500 mg per day (457). After a mean follow-up of 55 weeks (range, 19 to 107), 33 of the subjects assigned to placebo had the acquired immunodeficiency syndrome (AIDS), as compared with 11 of those assigned to receive 500 mg of zidovudine (P = 0.002; relative risk, 2.8; 95 percent confidence interval, 1.4 to 5.6) and 14 of those assigned to receive 1500 mg of zidovudine (P = 0.05; relative risk, 1.9; 95 percent confidence interval, 1.0 to 3.5). In the three treatment groups, the rates of progression (per 100 person-years) to either AIDS or advanced AIDS-related complex were 7.6, 3.6, and 4.3, respectively. As compared with those assigned to placebo, the subjects in the zidovudine groups had significant increases in the number of CD4+ cells and significant declines in p24 antigen levels. In the 1500-mg zidovudine group, severe hematologic toxicity (anemia or neutropenia) was more frequent than in the other groups (P<0.0001). In the 500-mg zidovudine group, nausea was the only toxicity that was significantly more frequent (in 3.3 percent) than in the placebo group (P = 0.001). We conclude that zidovudine is safe and effective in persons with asymptomatic HIV infection and fewer than 500 CD4+ cells per cubic millimeter. Additional study will be required to determine whether such treatment will ultimately improve survival for persons infected with HIV.

AB - Zidovudine (AZT) is a potent inhibitor of the replication of the human immunodeficiency virus (HIV), and it has been shown to improve survival in advanced HIV disease. We conducted a randomized, double-blind trial in adults with asymptomatic HIV infection who had CD4+ cell counts of fewer than 500 per cubic millimeter on entry into the study. The subjects (92 percent male) were randomly assigned to one of three treatment groups: placebo (428 subjects); zidovudine, 500 mg per day (453); or zidovudine, 1500 mg per day (457). After a mean follow-up of 55 weeks (range, 19 to 107), 33 of the subjects assigned to placebo had the acquired immunodeficiency syndrome (AIDS), as compared with 11 of those assigned to receive 500 mg of zidovudine (P = 0.002; relative risk, 2.8; 95 percent confidence interval, 1.4 to 5.6) and 14 of those assigned to receive 1500 mg of zidovudine (P = 0.05; relative risk, 1.9; 95 percent confidence interval, 1.0 to 3.5). In the three treatment groups, the rates of progression (per 100 person-years) to either AIDS or advanced AIDS-related complex were 7.6, 3.6, and 4.3, respectively. As compared with those assigned to placebo, the subjects in the zidovudine groups had significant increases in the number of CD4+ cells and significant declines in p24 antigen levels. In the 1500-mg zidovudine group, severe hematologic toxicity (anemia or neutropenia) was more frequent than in the other groups (P<0.0001). In the 500-mg zidovudine group, nausea was the only toxicity that was significantly more frequent (in 3.3 percent) than in the placebo group (P = 0.001). We conclude that zidovudine is safe and effective in persons with asymptomatic HIV infection and fewer than 500 CD4+ cells per cubic millimeter. Additional study will be required to determine whether such treatment will ultimately improve survival for persons infected with HIV.

UR - http://www.scopus.com/inward/record.url?scp=0025238899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025238899&partnerID=8YFLogxK

M3 - Article

C2 - 1969115

AN - SCOPUS:0025238899

VL - 322

SP - 941

EP - 949

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 14

ER -